CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Mesalamine +1 moredrug
Likely dose
Mesalamine 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01088243
NCT01088243Phase 2Completed
CompareCT.gov

Targeting Oxidative Stress in Chronic Beryllium Disease

National Jewish Health·interventional·Posted Mar 17, 2010·Updated Oct 12, 2018

In Brief

A Phase 2 clinical trial evaluating Mesalamine and Placebo for Chronic Beryllium Disease. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The purpose of this study is to understand if a drug called mesalamine helps to control inflammation associated with chronic beryllium disease (CBD). We hypothesize that in CBD subjects treated with prednisone, mesalamine treatment will enhance the immunosuppressive effects of prednisone, and thus reduce the immune response to beryllium.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Beryllium Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 17, 2010
Enrollment StartMar 1, 2010
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 16.3 years ago

Interventions

Mesalaminedrug

Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.

Placebodrug

Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.